Key result
Olmesartan medoxomil and azelnidipine significantly reduced the expansion rate of experimental abdominal aortic aneurysms in hamsters compared to control (6.2% and 12.2% vs 55.6%, p<0.01).
Why the study?
Does olmesartan medoxomil or azelnidipine reduce aortic diameter expansion and MMP levels in a hamster model of abdominal aortic aneurysm?
Does olmesartan medoxomil or azelnidipine reduce aortic diameter expansion and MMP levels in a hamster model of abdominal aortic aneurysm?
Both olmesartan and azelnidipine significantly suppressed abdominal aortic aneurysm expansion and decreased MMP-9 activity in an elastase-induced hamster model.
Answers are grounded in this paper and cite their sources.
Does not support clinical AAA use; leaves open translation from hamster model to human trials.
Remodeling in the abdominal aortic wall results in abdominal aortic aneurysm (AAA) formation. Many patients with AAA are prescribed antihypertensive drugs. However, the effects of antihypertensive drugs other than their effects on blood pressure control are rarely reported. In this study, we investigated the effects of these drugs on changes in the levels of matrix metalloproteinases (MMPs) and on AAA formation. Experimental AAAs were created in a hamster model by wrapping the abdominal aorta with elastase gauze. Olmesartan medoxomil (angiotensin II receptor antagonist) or azelnidipine (calcium channel antagonist) was administered to the hamsters and then we evaluated the aortic diameter, performed histological analysis, and analyzed the production of MMP-2 and MMP-9 by gelatin zymography. The expansion rate of the aortic diameter was smaller in both treatment groups than in the control group. Elastica van Gieson (EVG) staining showed structural preservation of elastin lamellae in both treatment groups. The active MMP-9 level decreased in both the olmesartan group and the azelnidipine group. Reducing MMP-9 production is important for suppression of AAA formation. Both olmesartan medoxomil and azelnidipine decreased MMP-9 activity, which suppressed degradation of the MMPs and inhibited AAA formation. There are different cascades that determine the production of MMP-9.
No takes yet. Share an insight, caveat, or question.
Yukio Hosokawa (2010) studied Experimental abdominal aortic aneurysm (n=40). Olmesartan medoxomil or Azelnidipine vs. Placebo (0.5% carboxymethyl cellulose) was evaluated on Expansion rate of external aortic diameter (EAD) at 21 days (p=<0.01). Olmesartan medoxomil and azelnidipine significantly reduced the expansion rate of experimental abdominal aortic aneurysms in hamsters compared to control (6.2% and 12.2% vs 55.6%, p<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: